Top

DoW Melanoma Research Program Focused Program Award – Rare Melanomas

Active

Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

The fiscal year 2026 Melanoma Research Program Focused Program Award for Rare Melanomas, solicitation number HT942526MRPFPARM, is a multidisciplinary research funding opportunity issued by the Defense Health Agency. The program supports a team consisting of one Initiating Principal Investigator and one to two Partnering Principal Investigators who must collaborate on two to three complementary research projects addressing an overarching question relevant to rare melanomas. A critical requirement for the project team is the inclusion of at least one rare melanoma survivor or patient advocate to provide consultation throughout the planning, implementation, and dissemination phases. Clinical trials are permitted, provided they adhere to registration and reporting requirements on ClinicalTrials.gov. The program expects to allot approximately 5.6 million dollars to fund roughly two awards, with a total cost cap of 2.8 million dollars per award over a maximum period of performance of four years. The application process is a two-tier system requiring a pre-application by July 13, 2026, followed by an invited full application due by October 14, 2026. Evaluation is based on a peer review of technical merit—focusing on the overarching question, research team, budget, environment, and presentation—followed by a programmatic review to determine relevance to military health and program objectives. Awardees must maintain active registrations in SAM.gov, eBRAP.org, and Grants.gov and are required to participate in a milestone meeting during the third year of performance.

General Info

DHA funding for rare melanoma research teams, up to $2.8 million over four years.

Agency

Department Of Defense → Department Of The Army -- Usamraa

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Place of Performance

Not specified

Set-Aside

NONE

Documents

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

Timeline

PostedMay 5

forecast

Ready to pursue this opportunity?

Get full access to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

AgencyDepartment Of Defense → Department Of The Army -- Usamraa

Contacts1 person available

OfficeUSA

Organization / AgencyDepartment Of Defense → Department Of The Army -- Usamraa

Office AddressUSA

Contacts

eBRAP Help Desk

contact@example.gov

+1 (555) 000-0000

Full Description

Summary: The fiscal year 2026 (FY26) Melanoma Research Program (MRP) Focused Program Award – Rare Melanomas, supports a multidisciplinary research program of at least two, but not more than three, distinct but complementary research projects addressing an overarching question relevant to rare melanomas.

Distinctive Features:

· *Updated for FY26* Investigators must include at least one rare melanoma survivor or patient advocate as part of the project team who will provide advice and consultation throughout planning, implementation, and results dissemination to maximize research impact.

· This is a partnering mechanism, requiring an Initiating Principal Investigator (PI) and at least one, but not more than two, Partnering PIs, see Figure 1.

○ Each named PI is expected to be a Project Leader for one of the proposed research projects. If recommended for funding, each PI will be named on separate awards to the recipient organization(s).

· After submitting the required pre-application, investigators must receive an invitation to submit a full application.

○ Only the Initiating PI will submit a pre-application. All PIs must submit full applications. The Partnering PI(s)’s application is an abbreviated package specific to their proposed research project.

· Clinical trials are allowed.

Funding Details: The Congressionally Directed Medical Research Programs expects to allot roughly $5.6M to fund approximately 2 Focused Program Award – Rare Melanomas applications with total cost caps of $2.8M per award. The maximum period of performance is 4 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.